TABLE 3.

Summary of results from combination studies of GSK364735 and approved antiretrovirals^a

Compound	Deviation from additivity			Interaction with GSK364735
	Average	SE	P (t test)b
GSK364735	−0.013	0.035	0.357	Additive
NRTIs
Zidovudine	−0.388	0.016	3.4E-08	Synergistic
Stavudine	−0.064	0.034	0.051	Additive
Dideoxycytosine	0.063	0.060	0.159	Additive
Dideoxyinosine	−0.162	0.062	0.0002	Synergistic
Abacavir	−0.111	0.039	0.010	Synergistic
3TC	−0.315	0.027	4.20E-06	Synergistic
Emtricitabine	−0.009	0.062	0.442	Additive
Tenofovir	−0.092	0.030	0.008	Synergistic
NNRTIs
Efavirenz	−0.006	0.051	0.452	Additive
Nevirapine	−0.108	0.032	0.004	Synergistic
Delavirdine	−0.144	0.027	0.00036	Synergistic
PIs
Indinavir	0.092	0.072	0.117	Additive
Lopinavir	−0.029	0.047	0.277	Additive
Nelfinavir	−0.239	0.051	0.0027	Synergistic
Ritonavir	0.050	0.049	0.169	Additive
Amprenavir	0.049	0.031	0.079	Additive
Saquinavir	0.025	0.054	0.327	Additive
Atazanavir	−0.058	0.072	0.223	Additive
Fusion inhibitor
Enfuvirtide (Fuzeon)	−0.197	0.047	0.003	Synergistic

^aAverage values and standard errors are from at least three determinations.

^bP is the probability that the deviation from additivity is equal to zero.